![Mark F. Kubik](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark F. Kubik
Corporate Officer/Principal at GENOR BIOPHARMA HOLDINGS LIMITED
Mark F. Kubik active positions
Companies | Position | Start | End |
---|---|---|---|
GENOR BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 2021-08-16 | - |
Career history of Mark F. Kubik
Former positions of Mark F. Kubik
Companies | Position | Start | End |
---|---|---|---|
OncoImmune, Inc.
![]() OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Corporate Officer/Principal | - | - |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-03-02 | - |
Training of Mark F. Kubik
University of Colorado Boulder | Undergraduate Degree |
The Leeds School of Business | Masters Business Admin |
Statistics
International
United States | 6 |
Cayman Islands | 2 |
Operational
Corporate Officer/Principal | 4 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
Private companies | 1 |
---|---|
OncoImmune, Inc.
![]() OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Mark F. Kubik
- Experience